114 results on '"C G, Begley"'
Search Results
2. Pure red cell aplasia of pregnancy: a distinct clinical entity
- Author
-
R. I. Baker, A. Manoharan, E. De, null Luca, and C. G. Begley
- Subjects
Adult ,medicine.medical_specialty ,Blood transfusion ,medicine.medical_treatment ,Pure red cell aplasia ,Red-Cell Aplasia, Pure ,Gastroenterology ,Immunoglobulin G ,Pregnancy ,Erythroblast ,hemic and lymphatic diseases ,Internal medicine ,Normal haemoglobin ,medicine ,Humans ,Blood Transfusion ,Aplastic anemia ,Erythropoietin ,biology ,business.industry ,Pregnancy Complications, Hematologic ,Hematology ,Hematopoietic Stem Cells ,medicine.disease ,Immunology ,biology.protein ,Gestation ,Female ,business - Abstract
We describe a 31-year-old patient with pure red cell aplasia of pregnancy, successfully managed with regular blood transfusions. In vitro studies showed specific inhibition of day 14 erythroid colonies (BFU-E) using serum and purified immunoglobulin G (IgG) obtained from the patient at diagnosis (before blood transfusion). The inhibition of BFU-E disappeared when haematological remission occurred 3 weeks after delivery and she remains clinically well with a normal haemoglobin 4 years later.
- Published
- 2008
3. Cytotoxicity of Paclitaxel or Cisplatin on Carcinoma Cell Lines is not Inhibited by Leukemia Inhibitory Factor (LIF)
- Author
-
C G Begley, Wendy D. Cook, S L Grant, E O'Flaherty, J Boyd, and J Kurek
- Subjects
endocrine system ,Time Factors ,Leukemia Inhibitory Factor Receptor alpha Subunit ,Paclitaxel ,Receptors, OSM-LIF ,medicine.medical_treatment ,Clinical Biochemistry ,Pharmacology ,Leukemia Inhibitory Factor ,chemistry.chemical_compound ,Endocrinology ,Antigens, CD ,Cytokine Receptor gp130 ,Tumor Cells, Cultured ,medicine ,Humans ,RNA, Messenger ,Receptors, Cytokine ,Cytotoxicity ,reproductive and urinary physiology ,Cisplatin ,Lymphokines ,Chemotherapy ,Membrane Glycoproteins ,Dose-Response Relationship, Drug ,Interleukin-6 ,Reverse Transcriptase Polymerase Chain Reaction ,urogenital system ,business.industry ,Carcinoma ,Cell Differentiation ,Cell Biology ,Antineoplastic Agents, Phytogenic ,Growth Inhibitors ,chemistry ,MCF-7 ,Cell culture ,embryonic structures ,business ,Leukemia inhibitory factor ,Cell Division ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
We have established a reliable, reproducible and objective growth assay to measure whether leukemia inhibitory factor (LIF) was able to protect tumour-derived cell lines from toxic effects of the chemotherapy agents, cisplatin and paclitaxel. Using this assay, we demonstrated that LIF did not alter the cytotoxic action of these drugs, on a panel of seven cancer cell lines. This was not because of the inactivity of the LIF or because the cell lines did not express components of the LIF receptor. These findings suggest that the potential clinical use of LIF, as a neuroprotective agent, in conjunction with chemotherapy will not interfere with the anti-tumour treatment.
- Published
- 2002
4. Thrombopoietin
- Author
-
R L, Basser and C G, Begley
- Subjects
Blood Platelets ,Cancer Research ,Thrombopoietin ,Oncology ,Neoplasms ,Hematopoietic Stem Cell Transplantation ,Humans ,General Medicine ,Hematopoietic Stem Cell Mobilization - Published
- 2001
5. Mice unresponsive to GM-CSF are unexpectedly resistant to cutaneous Leishmania major infection
- Author
-
Emanuela Handman, C G Begley, Joan M Curtis, Tracey M. Baldwin, Clare L. Scott, Lorraine Robb, and L Roe
- Subjects
medicine.medical_treatment ,Immunology ,Leishmaniasis, Cutaneous ,Receptors, Cell Surface ,In Vitro Techniques ,Nitric Oxide ,Microbiology ,Mice ,In vivo ,medicine ,Animals ,Peritoneal Lavage ,Leishmania major ,Beta (finance) ,Interleukin 5 ,biology ,Granulocyte-Macrophage Colony-Stimulating Factor ,Interleukin ,Receptors, Interleukin ,Receptors, Interleukin-5 ,Colony-stimulating factor ,biology.organism_classification ,Receptors, Interleukin-3 ,Mice, Inbred C57BL ,Infectious Diseases ,Granulocyte macrophage colony-stimulating factor ,Cytokine ,Receptors, Granulocyte-Macrophage Colony-Stimulating Factor ,Mutation ,Macrophages, Peritoneal ,Interleukin-3 ,Interleukin-5 ,medicine.drug - Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to play a protective role in leishmanial infection. Mice with a null mutation in the gene for the beta common (beta c) chain of the receptors for GM-CSF, interleukin(IL)-3 and IL-5 (beta c-null mice) display normal steady state hemopoiesis and develop lung disease similar to the human condition, alveolar proteinosis, due to a lack of signaling by GM-CSF. We therefore expected to observe a heightened sensitivity to Leishmania major in the beta c-null mice. Surprisingly, the beta c-null mice were more resistant to cutaneous infection than wild-type (wt) mice. Upon intradermal injection of L. major promastigotes, fewer beta c-null mice developed cutaneous lesions than wt mice and these lesions were smaller and healed more rapidly than in wt mice. This resistance to disease was associated with a reduced percentage of in vitro infected beta c-null macrophages. Macrophages from beta c-null mice displayed a more activated phenotype and produced increased amounts of nitric oxide following infection with L. major, both in vivo and in vitro. Paradoxically, however, the parasite burden in the draining lymph nodes was similar in both beta c-null and wt mice, suggesting that at least a subpopulation of cells was susceptible to the parasite. The mechanism preventing normal lesion development remains to be elucidated.
- Published
- 2000
6. Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assay
- Author
-
C. H. Hui, Russell L. Basser, C. G. Begley, L B To, M. J. Horsfall, and P. J. Simmons
- Subjects
Colony-forming unit ,Neutrophil Engraftment ,Cell ,Stem cell factor ,Hematology ,Biology ,Granulocyte ,Molecular biology ,Granulocyte colony-stimulating factor ,medicine.anatomical_structure ,Cell culture ,Immunology ,medicine ,Stem cell - Abstract
Fifty-two patients with poor prognosis carcinoma of the breast underwent peripheral blood stem cell (PBSC) mobilization using five different regimens. The yields of primitive haemopoietic progenitors were quantified by a recently described pre-colony-forming unit (pre-CFU) assay using limiting dilution analysis (LDA). Results of days 14 and 35 pre-CFU were also correlated with conventional CD34+ cell enumeration, CFU-GM (granulocyte–macrophage) and long-term culture-initiating cell (LTCIC) assays. The yield of pre-CFUs with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) was significantly higher than with G-CSF alone, cyclophosphamide (Cyclo) and granulocyte–monocyte colony-stimulating factor (GM-CSF), interleukin (IL)-3 and GM-CSF, or Cyclo alone. No significant correlation between neutrophil engraftment and pre-CFU could be demonstrated. Furthermore, CFU-GM was shown to bear a stronger correlation with pre-CFU and LTCIC than CD34+ cell measurement; thus, CFU-GM remains a useful biological tool for haemopoietic stem cell assay. We conclude that the combination of G-CSF and SCF mobilizes the highest number of pre-CFUs as measured by functional pre-CFU assay, which provides an alternative measurement of primitive haemopoietic progenitors to the LTCIC assay.
- Published
- 2000
7. Pharmacokinetic Analysis of Pegylated Megakaryocyte Growth and Development Factor in Humans
- Author
-
E Cheung, S Fox, Jonathan Cebon, Russell L. Basser, R H De Boer, C G Begley, J Marty, and L K Roskos
- Subjects
Injections, Subcutaneous ,medicine.medical_treatment ,Clinical Biochemistry ,Antineoplastic Agents ,Enzyme-Linked Immunosorbent Assay ,Absorption (skin) ,Pharmacology ,Drug Administration Schedule ,Polyethylene Glycols ,Endocrinology ,Megakaryocyte ,Pharmacokinetics ,Neoplasms ,medicine ,Humans ,Megakaryopoiesis ,Chemotherapy ,Dose-Response Relationship, Drug ,Platelet Count ,business.industry ,Biological activity ,Cell Biology ,Ligand (biochemistry) ,Recombinant Proteins ,Pharmacokinetic analysis ,medicine.anatomical_structure ,Thrombopoietin ,business - Abstract
Phase I studies with pegylated megakaryocyte growth and development factor (PEG-rHuMGDF), a c-Mpl ligand that stimulates megakaryopoiesis, have demonstrated that PEG-rHuMGDF is biologically active alone and causes a dose-related enhancement of platelet recovery when administered after chemotherapy. Here we report the dose-ranging pharmacokinetics of PEG-rHuMGDF. Pre-injection blood samples were drawn daily for pharmacokinetic studies on 43 patients. An ELISA, established using PEG-rHuMGDF as the standard, was able to quantitate Mpl ligand at concentrations0.02 ng/mL. Over the dose range 0.03 to 5.0 microg/kg/day, subcutaneous administration produced linear increases in steady-state serum levels. Maximum levels of PEG-rHuMGDF attained after 5.0 microg/kg/day were 5.88 to 10.9 ng/mL. After discontinuation of PEG-rHuMGDF, concentrations of Mpl ligand returned to baseline within 5 days. The pharmacokinetics were best described by a one-compartment model with first-order absorption, an absorption delay, and non linear clearance over the first 48 hours. The mean terminal half-life was 33.3 + 16.7 hours, and the average apparent at steady state was 27.7 + 14.0 mL/h/kg; both were independent of administered dose. The apparent clearance of PEG-rHuMGDF was not predicted by platelet count. Administration of chemotherapy and Filgrastim did not alter the pharmacokinetics of PEG-rHuMGDF.
- Published
- 2000
8. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor
- Author
-
P. J. Simmons, Russell L. Basser, C. G. Begley, L B To, B. W. Swart, and M. M. Roberts
- Subjects
medicine.medical_specialty ,Mobilization ,medicine.medical_treatment ,Growth factor ,Stem cell factor ,Hematology ,Biology ,Granulocyte colony-stimulating factor ,Andrology ,Transplantation ,Endocrinology ,Cytokine ,Internal medicine ,Precursor cell ,medicine ,Stem cell - Abstract
Mobilization of haemopoietic precursor cells into the circulation by the combination of cytokines, stem cell factor (SCF) and G-CSF in previously untreated patients with carcinoma of the breast resulted in increased yield of collected peripheral blood precursor cells (PBPC). This mobilization of PBPC by SCF with G-CSF lasted several days after ceasing the cytokines in comparison to the rapid fall of PBPC after ceasing G-CSF. Possible mechanisms for this increased and prolonged mobilization were investigated. Immunological phenotyping with CD38, Thy-1 and MDR-1 of the CD34-positive mobilized PBPC detected no difference in maturity compared to PBPC mobilized by G-CSF alone. However, the down-regulation of c-kit, which is associated with the mechanism of mobilization, was much greater in the PBPC mobilized by SCF and G-CSF. The potential clinical implication of increased and prolonged mobilization is increased yield, allowing transplantation of heavily pretreated patients, transplantation with PBPC from a single apheresis, or PBSC support for multiple courses of high-dose therapy from one mobilization procedure.
- Published
- 1999
9. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation
- Author
-
Lorraine Robb, Lynne Hartley, Frank Koentgen, Ruili Li, Harshal Hanumant Nandurkar, and C G Begley
- Subjects
medicine.medical_specialty ,Gene Expression ,In situ hybridization ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Andrology ,Mice ,Pregnancy ,Internal medicine ,Decidua ,medicine ,Animals ,Receptors, Interleukin-11 ,Interleukin-11 Receptor alpha Subunit ,Decidual cells ,Embryo Implantation ,Interleukin-11 receptor ,Uterus ,Decidualization ,Embryo ,Receptors, Interleukin ,General Medicine ,Interleukin-11 ,Mice, Mutant Strains ,Mice, Inbred C57BL ,Interleukin 11 ,Endocrinology ,medicine.anatomical_structure ,Female ,Infertility, Female ,Alpha chain - Abstract
During early pregnancy, in response to the implanting embryo, the surrounding uterine stroma undergoes a dramatic transformation into a specialized tissue known as the decidua. The de-cidua encapsulates the developing embryo, facilitating nutrient transfer and limiting tro-phoblast invasion. Here we show that female mice with a null mutation of the interleukin-11 receptor alpha chain are infertile because of defective decidualization. A temporal analysis revealed IL-11 expression is maximal in the normal pregnant uterus at the time of decidualization, and in situ hybridization studies showed expression of the IL-11 and the IL-11 receptor alpha chain in the developing decidual cells. These observations reveal a previously unrecognized critical role for IL-11 signaling in female reproduction.
- Published
- 1998
10. Identification of a Second Murine Interleukin-11 Receptor α-Chain Gene (IL11Ra2) with a Restricted Pattern of Expression
- Author
-
D J Hilton, L. Robb, C G Begley, and P T Brook-Carter
- Subjects
Untranslated region ,Receptor complex ,DNA, Complementary ,Molecular Sequence Data ,Interleukin 5 receptor alpha subunit ,Gene Expression ,Locus (genetics) ,Biology ,Interleukin 10 receptor, alpha subunit ,Mice ,Genetics ,Animals ,Receptors, Interleukin-11 ,Interleukin-11 Receptor alpha Subunit ,5-HT5A receptor ,Amino Acid Sequence ,Cloning, Molecular ,Interleukin-11 receptor ,Base Sequence ,Chromosome Mapping ,Interleukin ,Receptors, Interleukin ,Interleukin-11 ,Molecular biology ,Sequence Analysis - Abstract
The interleukin-11 receptor alpha-chain, a member of the hematopoietin receptor superfamily, forms, together with gp130, a functional high-affinity receptor complex for interleukin 11. We, and others, reported the cloning of the murine interleukin 11 receptor alpha-chain cDNA (IL11Ra) and recently described the structure of the IL11Ra locus. We also described the presence of a second IL11Ra-like locus in some mouse strains. In this study we report that the second locus, designated IL11Ra2, encodes an mRNA species. The transcript was 99% identical to the IL11Ra transcript in the coding and 3'-untranslated region, but had a different 5'-untranslated region. The complete genomic organization of the IL11Ra2 locus is presented, and the two loci are shown to be located on a 200-kb NaeI genomic fragment. Comparison of the expression pattern of the IL11Ra and IL11Ra2 genes using an RT-PCR restriction fragment length polymorphism strategy revealed that while the expression of IL11Ra was widespread, expression of IL11Ra2 was restricted to testis, lymph node, and thymus.
- Published
- 1997
11. Retroviral transduction of human progenitor cells: use of granulocyte colony-stimulating factor plus stem cell factor to mobilize progenitor cells in vivo and stimulation by Flt3/Flk-2 ligand in vitro
- Author
-
T Willson, H Zogos, Ngaire Elwood, and C G Begley
- Subjects
Growth factor ,medicine.medical_treatment ,Immunology ,Genetic transfer ,Stem cell factor ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Molecular biology ,Granulocyte colony-stimulating factor ,Transduction (genetics) ,Haematopoiesis ,medicine ,Cancer research ,Stem cell ,Progenitor cell - Abstract
The clinical application of gene transfer is hindered by the availability of the multipotential stem cells and the difficulty in obtaining efficient retroviral transduction. To assess potential means by which gene transfer into human hemopoietic stem cells might be enhanced, the retroviral transduction efficiency of human bone marrow cells (BM) or peripheral blood progenitor cells (PBPC) was compared at multiple time points after in vivo administration of granulocyte colony- stimulating factor (G-CSF). This was further compared with the transduction efficiency of cells mobilized with G-CSF plus stem cell factor (SCF) in a cohort of patients randomized to receive either one or two growth factors and with normal BM function. Using the LNL6 retrovirus, retroviral transduction efficiencies of up to 19% were observed for both PBPC and BM (n = 26 patients). There was at least a 100-fold increase in PBPC with G-CSF alone and a further 30-fold increase in the total number of progenitor cells available for retroviral transduction using the combination of SCF plus G-CSF. However, pretreatment of patients with G-CSF with or without SCF did not enhance the retroviral infectability of growth factor-mobilized progenitor cells. The effect of the growth factor, Flk-2/Flt3 ligand (FL), was also examined with respect to retroviral transduction efficiency of human progenitor cells. FL plus IL-3 in vitro increased the retroviral transduction efficiency up to eightfold compared with results observed using other combinations of cytokines tested (P < .001). These findings have clinical implications both for increasing the number of target cells for in vivo gene-marking/gene-therapy studies and improving the efficiency of gene transfer.
- Published
- 1996
12. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria
- Author
-
C G Begley, S Sassa, J. F. Mcmanus, and Sujiva Ratnaike
- Subjects
Genetics ,chemistry.chemical_classification ,Mutation ,Point mutation ,Uroporphyrinogen III decarboxylase ,Hepatoerythropoietic porphyria ,Immunology ,Cell Biology ,Hematology ,Biology ,medicine.disease_cause ,medicine.disease ,Biochemistry ,Stop codon ,Frameshift mutation ,Amino acid ,Exon ,chemistry ,medicine - Abstract
We describe five new mutations in the uroporphyrinogen decarboxylase (UROD) gene. All mutations were observed in conjunction with decreased erythrocyte UROD and clinical familial porphyria cutanea tarda (fPCT), (four families) or hepatoerythropoietic porphyria (HEP), (one family). The fPCT mutations included three point mutations that resulted in amino acid substitutions: a lysine to glutamine at amino acid position 253 (exon 7); a glycine to arginine at position 318 (exon 10); an isoleucine to threonine at position 334 (exon 10). The lysine to glutamine at amino acid position 253 was found in conjunction with a single C nucleotide deletion in exon 8 on the same allele of the UROD gene in the same family. This deletion resulted in a shift in the reading frame and the introduction of a premature stop codon 8 amino acids downstream. In the fourth family, a 31-bp deletion (nucleotides 828–858: exon 8) of the coding region, resulted in a frameshift and the introduction of a stop codon 19 amino acids downstream. A point mutation was observed in an individual diagnosed with HEP, resulting in an alanine to glycine change at amino acid position 80 and was present on both alleles. All mutations were confirmed in at least one other family member. The impact of these mutations on the function of the UROD protein was examined using in vitro protein expression and with activity assessed using pentacarboxylic acid porphyrinogen I as a substrate for UROD. Although three mutations reduced UROD activity to < 15% of normal, one resulted in a UROD protein with 50% functional activity and the other had near normal activity. These results indicate that many different genetic lesions of the UROD gene are associated with fPCT.
- Published
- 1996
13. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse
- Author
-
C G Begley, L. Robb, Andrew G. Elefanty, Louise Barnett, Frank Köntgen, Ngaire Elwood, and Ruili Li
- Subjects
animal structures ,General Immunology and Microbiology ,General Neuroscience ,fungi ,Gene targeting ,Biology ,behavioral disciplines and activities ,Null allele ,Molecular biology ,Embryonic stem cell ,General Biochemistry, Genetics and Molecular Biology ,Gene product ,Haematopoiesis ,Chimera (genetics) ,immune system diseases ,hemic and lymphatic diseases ,Stem cell ,Molecular Biology ,TAL1 - Abstract
Homozygosity for a null mutation in the scl gene causes mid-gestational embryonic lethality in the mouse due to failure of development of primitive hematopoiesis. Whilst this observation established the role of the scl gene product in primitive hematopoiesis, the death of the scl null embryos precluded analysis of the role of scl in later hematopoietic development. To address this question, we created embryonic stem cell lines with a homozygous null mutation of the scl gene (scl-/-) and used these lines to derive chimeric mice. Analysis of the chimeric mice demonstrates that the scl-/- embryonic stem cells make a substantial contribution to all non-hematopoietic tissues but do not contribute to any hematopoietic lineage. These observations reveal a crucial role for the scl gene product in definitive hematopoiesis. In addition, in vitro differentiation assays with scl-/- embryonic stem cells showed that the scl gene product was also required for formation of hematopoietic cells in this system.
- Published
- 1996
14. Lineage-restricted regulation of the murine SCL/TAL-1 promoter
- Author
-
AM Murrell, C. G. Begley, Ernesto Bockamp, L Robb, Berthold Göttgens, F McLaughlin, and Anthony R. Green
- Subjects
Ccaat-enhancer-binding proteins ,Basic helix-loop-helix ,Erythroid-Specific DNA-Binding Factors ,Cellular differentiation ,Immunology ,Promoter ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Molecular biology ,Chromatin ,hemic and lymphatic diseases ,Gene expression ,Transcription factor - Abstract
The SCL/TAL-1 gene encodes a basic helix-loop-helix transcription factor that is expressed in multipotent hematopoietic progenitors before lineage commitment. Its expression is maintained during differentiation along erythroid, mast, and megakaryocytic lineages, but is repressed after commitment to nonexpressing lineages. To begin to address the molecular mechanisms underlying this complex pattern of expression, we have studied the regulation of the murine SCL promoter in erythroid and T-cell lines. Analysis of the methylation and chromatin structure of the SCL promoter region showed that SCL mRNA expression correlated with DNase hypersensitive sites and methylation status of the promoter. Transient reporter assays showed that promoter 1a was active in erythroid cells but not in T cells. Sequences between - 187 and +26 were sufficient for lineage-restricted activity of promoter 1a. A joint promoter construct containing both promoter 1a and promoter 1b also exhibited lineage-restricted activity. Conserved GATA (-37), MAZ (+242), and ETS (+264) motifs were all shown to contribute to SCL promoter activity in erythroid cells, but several other motifs were not required for full promoter activity. The pattern of complexes binding to the +242 MAZ and +264 ETS sites were the same in erythroid and T cells. However, GATA-1 bound the -37 GATA site in erythroid cells, whereas in T cells GATA-3 was only able to bind weakly, if at all. Moreover, GATA-1 but not GATA-2 or GATA-3 was able to transactivate SCL promoter 1a in a T-cell environment. These results suggest that inactivity of SCL promoter 1a in T cells reflected the absence of GATA- 1 rather than the presence of trans-dominant negative regulators.
- Published
- 1995
15. Steel factor affects SCL expression during normal erythroid differentiation
- Author
-
Barbara A. Miller, J Floros, Laurie L. Bell, C Christian, C G Begley, J Kreider, Don M. Wojchowski, Ngaire Elwood, and Joseph Y. Cheung
- Subjects
Erythroid-Specific DNA-Binding Factors ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,fungi ,Immunology ,Stem cell factor ,Stimulation ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Andrology ,Haematopoiesis ,hemic and lymphatic diseases ,Erythropoiesis ,Northern blot ,Transcription factor - Abstract
Steel factor is one of the growth factors that controls the proliferation and differentiation of hematopoietic cells and SCL, also known as Tcl-5 or Tal-1, is a transcription factor involved in erythropoiesis. In this report, we studied the role of SCL in the proliferation of human peripheral blood burst-forming unit-erythroid (BFU-E) and the effects of Steel factor on SCL expression in proliferating erythroid cells. BFU-E-derived colonies increase progressively in size, as determined by cell number, from day 7 to day 14 of culture, with the greatest increase in colony size (10-fold expansion) occurring between day 7 and day 10. SCL protein levels in BFU-E-derived cells were highest in day 7 cells and decreased progressively from day 7 to day 14 of culture, suggesting an association of SCL with erythroid proliferation. In contrast, SCL mRNA levels did not decrease significantly between day 7 and day 14 cells, suggesting that posttranscriptional mechanisms are largely responsible for the decrease in SCL protein observed. The role of SCL in Steel factor-induced erythroid proliferation was then examined. In BFU-E- derived colonies cultured with Steel factor, colony size was significantly increased compared to control. In day 7 and day 10 erythroid precursors cultured with Steel factor, SCL protein was increased significantly compared to control. The increase in SCL protein levels in early erythroid precursors stimulated with Steel factor suggests one mechanism through which Steel factor may enhance normal erythroid proliferation. SCL mRNA levels assessed by Northern blot in day 7 cells did not increase significantly in response to Steel factor stimulation, suggesting that posttranscriptional mechanisms may also be important in the increase in SCL protein observed in response to Steel.
- Published
- 1994
16. Complex pattern of alternative splicing in the normal uroporphyrinogen decarboxylase gene: implications for diagnosis of familial porphyria cutanea tarda
- Author
-
Sujiva Ratnaike, J. F. Mcmanus, and C. G. Begley
- Subjects
Genetics ,congenital, hereditary, and neonatal diseases and abnormalities ,Uroporphyrinogen III decarboxylase ,Biochemistry (medical) ,Clinical Biochemistry ,Alternative splicing ,Intron ,nutritional and metabolic diseases ,Biology ,medicine.disease ,Molecular biology ,genomic DNA ,Exon ,Porphyria ,Consensus sequence ,medicine ,splice ,skin and connective tissue diseases - Abstract
We describe multiple alternative transcripts of uroporphyrinogen decarboxylase mRNA in normal individuals and patients with familial porphyria cutanea tarda. mRNA was reverse-transcribed, subjected to the polymerase chain reaction, and analyzed for nucleotide sequence. Seven different transcripts were characterized, and a cryptic splice acceptor site was identified in intron 1. In all mRNAs the exons abutted at previously defined exon boundaries. Characterization of the splice junctions in the genomic DNA showed that splice donor and acceptor sequences complied with the consensus sequences for these sites except for the splice acceptor sequences of exons 3 and 10. THese deviations were present in two normal individuals and one patient with familial porphyria cutanea tarda and were thus unable to explain the multiple aberrant uroporphyrinogen decarboxylase transcripts. We conclude that apparent deletions observed in transcripts derived from the uroporphyrinogen decarboxylase gene in patients with familial porphyria cutanea tarda should be interpreted with caution.
- Published
- 1994
17. Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction
- Author
-
Tracy A. Willson, D. Metcalf, Douglas J. Hilton, Nicos A. Nicola, Adrienne A. Hilton, Steven Rakar, C G Begley, M. Harrison-Smith, A Raicevic, and Nicholas M. Gough
- Subjects
DNA, Complementary ,Molecular Sequence Data ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Cell Line ,Mice ,Antigens, CD ,Cytokine Receptor gp130 ,Animals ,Receptors, Interleukin-11 ,Interleukin-11 Receptor alpha Subunit ,Amino Acid Sequence ,RNA, Messenger ,Leukemia Inhibitory Factor Receptor alpha Subunit ,Cloning, Molecular ,Receptor ,Molecular Biology ,Interleukin-11 receptor ,Membrane Glycoproteins ,Base Sequence ,Sequence Homology, Amino Acid ,General Immunology and Microbiology ,cDNA library ,General Neuroscience ,Oncostatin M ,3T3 Cells ,Receptors, Interleukin ,Glycoprotein 130 ,Molecular biology ,biology.protein ,Signal transduction ,Cytokine receptor ,Cell Division ,Signal Transduction ,Research Article - Abstract
An adult mouse liver cDNA library was screened with oligonucleotides corresponding to the conserved WSXWS motif of the haemopoietin receptor family. Using this method, cDNA clones encoding a novel receptor were isolated. The new receptor, named NR1, was most similar in sequence and predicted structure to the alpha-chain of the IL-6 receptor and mRNA was expressed in the 3T3-L1 pre-adipocytic cell line and in a range of primary tissues. Expression of NR1 in the factor-dependent haemopoietic cell line Ba/F3 resulted in the generation of low affinity receptors for IL-11 (Kd approximately 10 nM). The capacity to bind IL-11 with high affinity (Kd = 300-800 pM) appeared to require coexpression of both NR1 and gp130, the common subunit of the IL-6, leukaemia inhibitory factor (LIF), oncostatin M (OSM) and ciliary neurotrophic factor (CNTF) receptors. The expression of both NR1 and gp130 was also necessary for Ba/F3 cells to proliferate and M1 cells to undergo macrophage differentiation in response to IL-11.
- Published
- 1994
18. Hereditary Protein C Deficiency Associated with Mutations in Exon IX of the Protein C Gene
- Author
-
Rowan G. Doig, Katherine M McGrath, and C G Begley
- Subjects
Serine protease ,Genetics ,Mutation ,biology ,Point mutation ,Hematology ,medicine.disease ,medicine.disease_cause ,Molecular biology ,chemistry.chemical_compound ,5-Methylcytosine ,CpG site ,chemistry ,Protein C deficiency ,biology.protein ,medicine ,Gene ,Cytosine - Abstract
SummaryThis report describes five families with symptomatic hereditary protein C deficiency. Using a polymerase chain reaction (PCR)-based method, the entire coding sequence and intron-exon boundaries of the protein C gene was amplified from genomic DNA. In each family a single point mutation in the protein C gene was identified. Two unrelated families were found to share the same mutation, while the other three had different mutations. In the first two families with type I protein C deficiency the normal cytosine residue at nucleotide position 8551 in the protein C gene was replaced by thymidine leading to substitution of the normal proline residue at amino acid position 279 by leucine. In the third family with type I deficiency a previously undescribed mutation was identified. In this family the guanosine residue at position 8559 was replaced by adenosine (glycine 282 substituted by serine). In the fourth family, also with type I deficiency, guanosine 8589 was replaced by adenosine (glycine 292 substituted by serine). The fifth family had type II deficiency and in affected members cytosine 8769 was replaced by thymidine (arginine 352 substituted by tryptophan). All these mutations lead to amino acid substitutions in the serine protease domain of the mature protein. All were able to be confirmed by restriction enzyme analysis of PCR-derived DNA. In addition the novel mutation at nucleotide position 8559 was also demonstrable using single strand conformation polymorphism (SSCP) analysis of PCR-derived DNA. These mutations were likely examples of deamination of methylated cytosine occurring in cytosine-phosphate-guanosine (CpG) dinucleotide sequences. These findings confirm the genetic heterogeneity of hereditary protein C deficiency in these families.
- Published
- 1994
19. Molecular characterization of NSCL, a gene encoding a helix-loop-helix protein expressed in the developing nervous system
- Author
-
Irving Kirsch, Nicholas M. Gough, V Göbel, V L Bertness, Anthony R. Green, Stanley Lipkowitz, K A Mahon, and C G Begley
- Subjects
Molecular Sequence Data ,Gene Expression ,Nerve Tissue Proteins ,Molecular cloning ,Biology ,Nervous System ,Mice ,Complementary DNA ,Gene expression ,Basic Helix-Loop-Helix Transcription Factors ,Animals ,Coding region ,Amino Acid Sequence ,RNA, Messenger ,Cloning, Molecular ,Gene ,Peptide sequence ,Multidisciplinary ,Base Sequence ,cDNA library ,Nucleic acid sequence ,Blotting, Northern ,Molecular biology ,DNA-Binding Proteins ,Genes ,Sequence Alignment ,Research Article - Abstract
We report here the molecular cloning and chromosomal localization of an additional member of the helix-loop-helix (HLH) family of transcription factors, NSCL. The NSCL gene was identified based on its hybridization to the previously described hemopoietic HLH gene, SCL. Murine NSCL cDNA clones were obtained from a day 11.5 mouse embryo cDNA library. The coding region is 399 base pairs and encodes a predicted protein of 14.8 kDa. The nucleotide sequence shows 71% identity and the amino acid sequence shows 61% identity to murine SCL in the HLH domain. The NSCL protein-coding region terminates six amino acids beyond the second amphipathic helix of the HLH domain. Expression of NSCL was detected in RNA from mouse embryos between 9.5 and 14.5 days postcoitus, with maximum levels of expression at 10.5-12 days. Examination of 12- and 13-day mouse embryos by in situ hybridization revealed expression of NSCL in the developing nervous system. The NSCL gene was mapped to murine chromosome 1. The very restricted pattern of NSCL expression suggests an important role for this HLH protein in neurological development.
- Published
- 1992
20. G-CSF Mobilised Progenitor Cells in Autologous Transplantation
- Author
-
W. Sherid, D. Watson, Jeff Szer, Christopher A. Juttner, E. Deluca, P. A. Rowlings, Richard M. Fox, George Morstyn, and C G Begley
- Subjects
Chemotherapy ,Nutrition and Dietetics ,Platelet Engraftment ,business.industry ,medicine.medical_treatment ,Medicine (miscellaneous) ,Significant elevation ,In vitro ,In vivo ,Immunology ,Medicine ,Autologous transplantation ,Platelet ,Progenitor cell ,business - Abstract
G-CSF administration leads to significant elevation in the levels of circulating progenitor cells. Infusion of these cells after high-dose chemotherapy is associated with accelerated platelet engraftment that has a considerable impact in shortening thrombocytopenia and reducing need for platelet transfusions.
- Published
- 1992
21. SCL and related hemopoietic helix‐loop‐helix transcription factors
- Author
-
C G Begley and A. R. Green
- Subjects
Erythrocytes ,Myeloid ,T-Lymphocytes ,Cellular differentiation ,T cell ,Biology ,Translocation, Genetic ,Proto-Oncogene Proteins ,hemic and lymphatic diseases ,Basic Helix-Loop-Helix Transcription Factors ,Tumor Cells, Cultured ,medicine ,Animals ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Transcription factor ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,Basic helix-loop-helix ,fungi ,Cell Differentiation ,Cell Biology ,Molecular biology ,Hematopoiesis ,DNA-Binding Proteins ,Haematopoiesis ,medicine.anatomical_structure ,Cell culture ,Transcription Factors ,K562 cells - Abstract
The helix-loop-helix (HLH) proteins are a family of transcription factors that include proteins critical to differentiation and development in species ranging from plants to mammals. Five members of this family (MYC, SCL, TAL-2, LYL-1 and E2A) are implicated in oncogenic events in human lymphoid tumors because of their consistent involvement in chromosomal translocations. Although activated in T cell leukemias, expression of SCL and LYL-1 is low or undetectable in normal T cell populations. SCL is expressed in erythroid, megakaryocyte and mast cell populations (the same cell lineages as GATA-1, a zinc-finger transcription factor). In addition, both SCL and GATA-1 undergo coordinate modulation during chemically induced erythroid differentiation of mouse erythroleukemia cells and are down-modulated during myeloid differentiation of human K562 cells, thus implying a role for SCL in erythroid differentiation events. However, in contrast to GATA-1, SCL is expressed in the developing brain. Studies of the function of SCL suggest it is also important in proliferation and self-renewal events in erythroid cells.
- Published
- 1992
22. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood
- Author
-
Carolyn A. Felix, David G. Poplack, Gregory H. Reaman, Ilan R. Kirsch, Seth M. Steinberg, B J Taylor, C G Begley, and Diane E. Cole
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Genotype ,Receptors, Antigen, T-Cell ,Biology ,Gene Rearrangement, T-Lymphocyte ,Germline ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,medicine ,Humans ,Receptors, Immunologic ,Child ,B cell ,Retrospective Studies ,Lymphoblast ,T-cell receptor ,Cytogenetics ,Infant ,hemic and immune systems ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Molecular biology ,Phenotype ,medicine.anatomical_structure ,Oncology ,Child, Preschool ,T-Cell Receptor Gene ,Immunology ,biology.protein ,Antibody - Abstract
Immunoglobulin (Ig) and T-cell receptor (TCR) genes were examined in the lymphoblasts of 70 children with immunophenotypically defined B-cell precursor acute lymphoblastic leukemia (ALL). The most frequent genes to rearrange were Ig heavy (H) chain (93%) and TCR delta (79%), followed by TCR gamma (49%), Ig kappa and/or lambda light (L) chain (46%), TCR alpha (46%), and TCR beta (29%). Thus, despite their putative "B-cell precursor" lineage, these leukemias manifest a remarkably high incidence of TCR gene rearrangements. While certain patterns predominate, there is considerable heterogeneity in Ig and TCR genotypes in this disease. No significant associations were found between Ig and TCR genotype and commonly used prognostic factors including age, sex, race, WBC, French-American-British (FAB) subtype, or cytogenetics. However, the lymphoblasts of three of six patients who failed to achieve initial remission had germline patterns of every Ig and TCR gene, a genotype not observed in the leukemic cells from any of the 64 patients who achieved complete remission (p2 = .0007). This study suggests that particular Ig and TCR genotypes may be of clinical relevance in childhood B-cell precursor ALL. The finding of rearranged TCR genes in a large proportion of cases raises fundamental questions about early lineage commitment and lymphocyte differentiation along B-cell and T-cell pathways.
- Published
- 1990
23. G-CSF-mobilized peripheral and autologous bone marrow infusion following high dose chemotherapy
- Author
-
George Morstyn, Katherine M McGrath, L. B. To, D. Maher, Christopher A. Juttner, Jeff Szer, Richard M. Fox, C G Begley, and William P. Sheridan
- Subjects
Pathology ,medicine.medical_specialty ,High dose chemotherapy ,medicine ,Molecular Medicine ,Cell Biology ,Biology ,Autologous bone ,Developmental Biology ,Peripheral - Published
- 1992
24. The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor
- Author
-
H H, Nandurkar, L, Robb, and C G, Begley
- Subjects
Mice, Knockout ,Mice ,Mutagenesis, Site-Directed ,Animals ,Humans ,Receptors, Interleukin-11 ,Interleukin-11 Receptor alpha Subunit ,Receptors, Interleukin ,Interleukin-11 ,Hematopoiesis - Abstract
Interleukin 11 (IL-11) is a pleiotropic growth factor with several actions in common with members of the IL-6 family. IL-11 utilizes a specific receptor chain encoded by two genes, IL-11Ra, which is expressed in hematopoietic and other tissues and, IL-11Ra2, which has a restricted pattern of expression. The actions of IL-11 in the hematopoietic compartment include support of multilineage and committed progenitors contributing to myeloid, erythroid, megakaryocyte, and lymphoid lineages. IL-11 demonstrates a prominent thrombopoietic activity which is being evaluated in clinical trials. In contrast to the multiple in vitro and in vivo effects of IL-11, mice with a targeted mutation of the IL-11Ra gene (IL-11Ra-/-) did not exhibit an overt hematological phenotype. Generation of a null phenotype was confirmed by independent assays. The numbers of progenitor cells of various lineages as well as their terminally differentiated progeny were undisturbed in the IL-11Ra-/- mice. In addition, the mutant mice were able to respond appropriately to increased demand in situations of hematopoietic stress. This study has highlighted the growth factor redundancy operative in the hematopoietic compartment, and in addition, has served to identify a critical action of IL-11 in nonhematopoietic organs.
- Published
- 2000
25. Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assay
- Author
-
M J, Horsfall, C H, Hui, L B, To, C G, Begley, R L, Basser, and P J, Simmons
- Subjects
Stem Cell Factor ,Time Factors ,Interleukin-6 ,Hematopoietic Stem Cell Transplantation ,Granulocyte-Macrophage Colony-Stimulating Factor ,Antigens, CD34 ,Breast Neoplasms ,Hematopoietic Stem Cell Mobilization ,Colony-Forming Units Assay ,Granulocyte Colony-Stimulating Factor ,Humans ,Female ,Interleukin-3 ,Lymphocyte Count ,Cyclophosphamide ,Cells, Cultured ,Immunosuppressive Agents - Abstract
Fifty-two patients with poor prognosis carcinoma of the breast underwent peripheral blood stem cell (PBSC) mobilization using five different regimens. The yields of primitive haemopoietic progenitors were quantified by a recently described pre-colony-forming unit (pre-CFU) assay using limiting dilution analysis (LDA). Results of days 14 and 35 pre-CFU were also correlated with conventional CD34+ cell enumeration, CFU-GM (granulocyte-macrophage) and long-term culture-initiating cell (LTCIC) assays. The yield of pre-CFUs with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) was significantly higher than with G-CSF alone, cyclophosphamide (Cyclo) and granulocyte-monocyte colony-stimulating factor (GM-CSF), interleukin (IL)-3 and GM-CSF, or Cyclo alone. No significant correlation between neutrophil engraftment and pre-CFU could be demonstrated. Furthermore, CFU-GM was shown to bear a stronger correlation with pre-CFU and LTCIC than CD34+ cell measurement; thus, CFU-GM remains a useful biological tool for haemopoietic stem cell assay. We conclude that the combination of G-CSF and SCF mobilizes the highest number of pre-CFUs as measured by functional pre-CFU assay, which provides an alternative measurement of primitive haemopoietic progenitors to the LTCIC assay.
- Published
- 2000
26. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor
- Author
-
T, Gainsford, H, Nandurkar, D, Metcalf, L, Robb, C G, Begley, and W S, Alexander
- Subjects
Blood Platelets ,Mice, Knockout ,Lymphokines ,Genotype ,Interleukin-6 ,Platelet Count ,Bone Marrow Cells ,Hematopoietic Stem Cells ,Interleukin-11 ,Leukemia Inhibitory Factor ,Growth Inhibitors ,Hematopoiesis ,Neoplasm Proteins ,Mice ,Thrombopoietin ,Proto-Oncogene Proteins ,Animals ,Receptors, Cytokine ,Megakaryocytes ,Receptors, Thrombopoietin ,Spleen - Abstract
Mice lacking thrombopoietin (TPO) or its receptor c-Mpl are severely thrombocytopenic, consistent with a dominant physiological role for this cytokine in megakaryocytopoiesis. However, these mice remain healthy and show no signs of spontaneous hemorrhage, implying that TPO-independent mechanisms for platelet production exist and are sufficient for hemostasis. To investigate the roles of cytokines that act through the gp130 signaling chain in the residual platelet production of mpl (-/-) mice, mpl (-/-)IL-6(-/-), mpl(-/-)LIF(-/-), and mpl(-/-)IL-11Ralpha(-/-) double-mutant mice were generated. In each of these compound mutants, the number of circulating platelets was no lower than that observed in mice lacking only the c-mpl gene. Moreover, the deficits in the numbers of megakaryocytes and megakaryocyte progenitor cells in the bone marrow and spleen were no further exacerbated in mpl(-/-)IL-6(-/-), mpl(-/-)LIF(-/-), or mpl(-/-)IL-11Ralpha(-/-) double-mutant mice compared with those in Mpl-deficient animals. In single IL-6(-/-), LIF(-/-), and IL-11Ralpha(-/-) mutant mice, platelet production was normal. These data establish that, as single regulators, IL-6, IL-11, and LIF have no essential role in normal steady-state megakaryocytopoiesis, and are not required for the residual megakaryocyte and platelet production seen in the c-mpl(-/-) mouse. (Blood. 2000;95:528-534)
- Published
- 2000
27. An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors
- Author
-
Angus M. Sinclair, Maureen L. Stanley, María José Sánchez, Susie Hunter, Berthold Göttgens, C. G. Begley, and Anthony R. Green
- Subjects
Male ,Mesoderm ,Population ,Mice, Transgenic ,Biology ,Colony-Forming Units Assay ,Mice ,Vasculogenesis ,Pregnancy ,Proto-Oncogene Proteins ,medicine ,Basic Helix-Loop-Helix Transcription Factors ,Animals ,Yolk sac ,education ,Enhancer ,Molecular Biology ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,Yolk Sac ,Mice, Knockout ,education.field_of_study ,Helix-Loop-Helix Motifs ,Gene Expression Regulation, Developmental ,Hematopoietic Stem Cells ,Embryonic stem cell ,Cell biology ,Hematopoiesis ,DNA-Binding Proteins ,Mice, Inbred C57BL ,Haematopoiesis ,medicine.anatomical_structure ,Enhancer Elements, Genetic ,Lac Operon ,Immunology ,Mice, Inbred CBA ,Female ,Bone marrow ,Endothelium, Vascular ,Developmental Biology ,Transcription Factors - Abstract
The SCL gene encodes a basic helix-loop-helix transcription factor which is expressed in early haematopoietic progenitors throughout ontogeny and is essential for the normal development of blood and blood vessels. Transgenic studies have characterised spatially distinct 5′ enhancers which direct lacZ expression to subdomains of the normal SCL expression pattern, but the same elements failed to produce appropriate haematopoietic expression. We now describe an SCL 3′ enhancer with unique properties. It directed lacZ expression in transgenic mice to extra-embryonic mesoderm and subsequently to both endothelial cells and to a subset of blood cells at multiple sites of embryonic haematopoiesis including the yolk sac, para-aortic splanchnopleura and AGM region. The 3′ enhancer also targeted expression to haematopoietic progenitors in both foetal liver and adult bone marrow. Purified lacZ(+)cells were highly enriched for clonogenic myeloid and erythroid progenitors as well as day-12 spleen colony forming units (CFU-S). Within the total gated population from bone marrow, 95% of the myeloid and 90% of the erythroid colony-forming cells were contained in the lacZ(+) fraction, as were 98% of the CFU-S. Activation of the enhancer did not require SCL protein. On the contrary, transgene expression in yolk sacs was markedly increased in an SCL−/− background, suggesting that SCL is subject to negative autoregulation. Alternatively the SCL−/− environment may alter differentiation of extra-embryonic mesoderm and result in an increased number of cells capable of expressing high levels of the transgene. Our data represents the first description of an enhancer that integrates information necessary for expression in developing endothelium and early haematopoietic progenitors at distinct times and sites throughout ontogeny. This enhancer provides a potent tool for the manipulation of haematopoiesis and vasculogenesis in vivo.
- Published
- 1999
28. Three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tarda. Mutation in brief no. 237. Online
- Author
-
J F, McManus, C G, Begley, S, Sassa, and S, Ratnaike
- Subjects
Porphyria Cutanea Tarda ,Mutation, Missense ,Humans ,Point Mutation ,Uroporphyrinogen Decarboxylase - Abstract
We have characterised three new mutations in the uroporphyrinogen decarboxylase gene in familial porphyria cutanea tarda. The first of these was a G to A substitution in the 5' splice junction of exon 4 which generated an mRNA that lacked exon 4. The second was a nonsense mutation in exon 5 which changed the arginine residue at position 142 to a stop codon, and the third mutation, also in exon 5, was a triple base substitution from nucleotide position 417 to 419. This mutation encompassed two codons but only changed the amino acid predicted from the second codon, resulting in the replacement of valine with glutamine at position 134. This missense mutation has been described previously by Meguro et al. 1994, on one allele in a compound heterozygote with hepatoerythropoietic porphyria. This is the third case of an hepatoerythropoietic porphyria mutation in an individual diagnosed with familial porphyria cutanea tarda.
- Published
- 1999
29. The SCL gene: from case report to critical hematopoietic regulator
- Author
-
C G, Begley and A R, Green
- Subjects
DNA-Binding Proteins ,Leukemia ,Proto-Oncogene Proteins ,Basic Helix-Loop-Helix Transcription Factors ,Animals ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,Translocation, Genetic ,Hematopoiesis ,Transcription Factors - Published
- 1999
30. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor
- Author
-
M M, Roberts, B W, Swart, P J, Simmons, R L, Basser, C G, Begley, and L B, To
- Subjects
Stem Cell Factor ,Antigens, CD34 ,Breast Neoplasms ,Flow Cytometry ,Hematopoietic Stem Cells ,Hematopoietic Stem Cell Mobilization ,Immunophenotyping ,Cohort Studies ,Drug Combinations ,Proto-Oncogene Proteins c-kit ,Phenotype ,Granulocyte Colony-Stimulating Factor ,Humans ,Female ,Leukapheresis - Abstract
Mobilization of haemopoietic precursor cells into the circulation by the combination of cytokines, stem cell factor (SCF) and G-CSF in previously untreated patients with carcinoma of the breast resulted in increased yield of collected peripheral blood precursor cells (PBPC). This mobilization of PBPC by SCF with G-CSF lasted several days after ceasing the cytokines in comparison to the rapid fall of PBPC after ceasing G-CSF. Possible mechanisms for this increased and prolonged mobilization were investigated. Immunological phenotyping with CD38, Thy-1 and MDR-1 of the CD34-positive mobilized PBPC detected no difference in maturity compared to PBPC mobilized by G-CSF alone. However, the down-regulation of c-kit, which is associated with the mechanism of mobilization, was much greater in the PBPC mobilized by SCF and G-CSF. The potential clinical implication of increased and prolonged mobilization is increased yield, allowing transplantation of heavily pre-treated patients, transplantation with PBPC from a single apheresis, or PBSC support for multiple courses of high-dose therapy from one mobilization procedure.
- Published
- 1999
31. Resolving conflicting signals: cross inhibition of cytokine signaling pathways
- Author
-
C G, Begley and N A, Nicola
- Subjects
Animals ,Cytokines ,Humans ,Cell Differentiation ,Cell Lineage ,Hematopoietic Stem Cells ,Hematopoiesis ,Signal Transduction - Published
- 1999
32. Repeatability of refraction and corrected visual acuity in keratoconus. The CLEK Study Group. Collaborative Longitudinal Evaluation of Keratoconus
- Author
-
L J, Davis, K B, Schechtman, C G, Begley, J A, Shin, and K, Zadnik
- Subjects
Adult ,Male ,Contact Lenses ,Visual Acuity ,Humans ,Reproducibility of Results ,Female ,Keratoconus ,Refraction, Ocular - Abstract
The purpose of the test-retest phase of the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study was to determine the repeatability of the various parts of the CLEK Study protocol. This paper presents the test-retest parameters of the refraction protocol.We examined 138 CLEK Study-eligible patients on two occasions (median, 90 days; range, 22 to 268 days). All patients underwent subjective refraction on two occasions, and contact lens over-refractions were performed either over the patient's habitual rigid contact lenses or over a trial rigid contact lens equal in base curve to the steep keratometric reading in nonrigid contact lens wearers.Mean interoccasion differences +/- SD were -0.32 +/- 2.91 D and -0.17 +/- 1.39 D for subjective refraction sphere and cylinder power, respectively, and the mean absolute difference for subjective refraction cylinder axis was 18.1 +/- 20.2 degrees. The mean interoccasion difference +/- SD for high-contrast visual acuity with subjective refraction was 0.38 +/- 10.9 letters correct. Mean interoccasion differences +/- SD were -0.11 +/- 0.81 D and 0.02 +/- 0.67 D for contact lens over-refraction sphere and cylinder power, respectively, and the mean absolute difference for contact lens over-refraction cylinder axis was 11.6 +/- 9.9 degrees. The mean interoccasion difference +/- SD for visual acuity with contact lens over-refraction was 0.50 +/- 5.2 letters correct and 0.71 +/- 6.9 letters correct for high- and low-contrast visual acuity, respectively.The repeatability of subjective refraction in keratoconus patients is good but somewhat lower than that found in nondiseased eyes. Only 36% of our repeat measures of sphere power from subjective refraction fell within 0.50 D of each other, compared with more than 90% in studies of normal eyes.
- Published
- 1999
33. Transcriptional Control of Hematopoiesis
- Author
-
L. Robb, C G Begley, and Andrew G. Elefanty
- Subjects
Transcriptional regulation ,Clone (cell biology) ,Compartment (development) ,Identification (biology) ,Computational biology ,Cell fate determination ,Molecular cloning ,Biology ,Bioinformatics ,Gene ,Transcription factor - Abstract
Publisher Summary The field of experimental hematology has advanced dramatically since the development of the clonal culture assay in the mid-1960s. This technique proved to be crucial for many reasons. The subsequent application of molecular cloning techniques allowed the genes encoding these extracellular growth factors, or colony-stimulating factors (CSFs), to be defined and recombinant molecules to be produced. The ability to molecularly clone mammalian genes also provided a new perspective for experimental hematologists. The knowledge that transcription factors were important in determining cell fate in other systems was quickly translated to hematopoietic cells, with identification of key transcriptional regulators. The application of molecular genetic techniques has provided entirely new approaches for dissecting the hematopoietic compartment. Some of the important transcription factors are reviewed in this chapter, where new insights into their role in hematopoiesis have been provided by using this approach. The chapter concludes by presenting a hopeful future that genetic approaches will continue to be vital in furthering our initial insights into the role of transcription factors in the regulation of hematopoiesis.
- Published
- 1999
34. Functional analysis of mature hematopoietic cells from mice lacking the betac chain of the granulocyte-macrophage colony-stimulating factor receptor
- Author
-
C L, Scott, D A, Hughes, D, Cary, N A, Nicola, C G, Begley, and L, Robb
- Subjects
Mice ,Receptors, Granulocyte-Macrophage Colony-Stimulating Factor ,Mutation ,Animals ,Granulocyte-Macrophage Colony-Stimulating Factor ,Cell Differentiation ,Receptors, Cell Surface ,Hematopoietic Stem Cells ,Signal Transduction - Abstract
Mice with a null mutation of the betac chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors (betac-null mice) develop an alveolar proteinosis-like lung disease. The pathogenesis of this disease is uncertain and, although a defect in alveolar macrophage function has been postulated, no previous analysis of mature hematopoietic cells in mice with alveolar proteinosis has been reported. Therefore, we undertook a functional analysis of the mature hematopoietic cell compartment in betac-null mice. In addition, we reexamined the roles of the GM-CSF receptor chain and the betac chain in signaling by GM-CSF. Neutrophils and macrophages from betac-null mice were capable of normal survival and phagocytosis in the absence of stimulus and of similar levels of nitric oxide production in response to interferon-gamma and lipopolysaccharide. GM-CSF-mediated augmentation of survival, phagocytosis, and hydrogen-ion production were absent in neutrophils from betac-null mice. Interestingly, we were unable to show any ability of the GM-CSF receptor -chain alone to mediate glucose transport in these cells. In keeping with the betac-null mice lung pathology, examination of lavage fluid from the lungs of betac-null mice showed increased cellularity. This was caused by an increase in the number of lymphocytes, neutrophils, and macrophages. Large foamy cells in the lavage fluid from betac-null mice were identified as macrophages using immunohistochemistry. Functional analysis showed that these betac-null alveolar macrophages were capable of phagocytosis but uptake of colloidal carbon and cellular adhesion were reduced. In summary, mature hematopoietic cells with a null mutation of the betac receptor were unable to perform GM-CSF-mediated hematopoietic cell functions including glucose transport, but responded normally to a range of other ligands.
- Published
- 1998
35. Characterization of cells shed from the ocular surface in normal eyes
- Author
-
C G, Begley, J, Zhou, and G, Wilson
- Subjects
Adult ,Contact Lenses ,Reference Values ,Epithelium, Corneal ,Humans ,Keratins ,Epithelial Cells ,Conjunctiva ,Immunohistochemistry ,Circadian Rhythm - Published
- 1998
36. Enhanced megakaryocyte and erythroid development from normal human CD34(+) cells: consequence of enforced expression of SCL
- Author
-
N J, Elwood, H, Zogos, D S, Pereira, J E, Dick, and C G, Begley
- Subjects
Adult ,Transcription, Genetic ,Recombinant Fusion Proteins ,Genetic Vectors ,Antigens, CD34 ,Apoptosis ,Bone Marrow Cells ,Transfection ,Colony-Forming Units Assay ,Hemoglobins ,Proto-Oncogene Proteins ,Basic Helix-Loop-Helix Transcription Factors ,Humans ,Cells, Cultured ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,Erythroid Precursor Cells ,Blood Cells ,Macrophages ,Cell Cycle ,Infant, Newborn ,Cell Differentiation ,Fetal Blood ,Hematopoietic Stem Cells ,Hematopoiesis ,DNA-Binding Proteins ,Retroviridae ,Gene Expression Regulation ,Megakaryocytes ,Granulocytes ,Transcription Factors - Abstract
The product of the SCL gene is a basic helix-loop-helix (bHLH) transcription factor that is essential for the development of hematopoietic stem cells in both the embryo and the adult. However, once the stem cell compartment is established, the function of SCL in subsequent differentiation and commitment events within normal hematopoietic cells remains undefined. The aim of the current study was to investigate this role using purified normal human hematopoietic CD34(+) cells. An SCL retrovirus was used to transduce CD34(+) cells isolated from human bone marrow, peripheral blood, and umbilical cord blood. Enforced expression of SCL increased by a median of twofold the number of erythroid colonies, with an increase in both colony size and the rate of hemoglobinization. Unexpectedly, enforced expression in CD34(+) cells also significantly increased the number of megakaryocyte colonies, but with no impact on the size of colonies. There was no consistent effect on the number nor size of granulocyte-macrophage (GM) colonies. The proliferative effect of enforced SCL expression on erythroid cells was attributed to a shortened cell cycle time; the self-renewal capacity of erythroid or GM progenitors was unchanged, as was survival of cells within colonies. These results demonstrate a role for SCL in determining erythroid and megakaryocyte differentiation from normal human hematopoietic CD34(+) cells.
- Published
- 1998
37. Repeatability and agreement of two corneal-curvature assessments in keratoconus: keratometry and the first definite apical clearance lens (FDACL). CLEK Study Group. Collaborative Longitudinal Evaluation of Keratoconus
- Author
-
T B, Edrington, L B, Szczotka, C G, Begley, D S, Burger, B S, Wilson, J T, Barr, K, Zadnik, and M O, Gordon
- Subjects
Adult ,Male ,Observer Variation ,Contact Lenses ,Reproducibility of Results ,Diagnostic Techniques, Ophthalmological ,Keratoconus ,Cornea ,Disease Progression ,Humans ,Female ,Child ,Follow-Up Studies ,Retrospective Studies - Abstract
This study was conducted to determine the agreement and test-retest repeatability of two methods for measuring corneal curvature in keratoconus: keratometry and the First Definite Apical Clearance Lens (FDACL). Our interest in the FDACL procedure stems from the important contact lens-fitting information and documentation of disease progression provided by the FDACL trial lenses and observation of fluorescein patterns.The Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study is an observational study that has enrolled 1,209 keratoconus patients to characterize the progression of keratoconus, to determine factors associated with its progression, and to assess its impact on quality of life. Ten percent of the patients were randomly selected at baseline for a retest examination. The baseline examination, which included keratometry and FDACL, was repeated in this sample. The FDACL is the flattest lens in the standardized CLEK trial lens set that vaults the apex of the cone. FDACL provides an estimate of the sagittal height of the cone.The correlation of FDACL with the steep keratometric reading (r = 0.89; p = 0.0001) and the flat keratometric reading (r = 0.83; p = 0.0001) were high. Test-retest repeatability as measured by the intraclass correlation coefficient (ICC) was high: FDACL ICC, 0.97; steep keratometric reading ICC, 0.96; and flat keratometric reading ICC, 0.95. Test-retest repeatability of FDACL remained high in advanced disease.FDACL provides a repeatable new procedure for determining disease severity in keratoconus.
- Published
- 1998
38. Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production
- Author
-
T, Gainsford, A W, Roberts, S, Kimura, D, Metcalf, G, Dranoff, R C, Mulligan, C G, Begley, L, Robb, and W S, Alexander
- Subjects
Blood Platelets ,Mice ,Thrombopoietin ,Proto-Oncogene Proteins ,Animals ,Cell Differentiation ,Interleukin-3 ,Receptors, Cytokine ,Megakaryocytes ,Receptors, Thrombopoietin ,Mice, Mutant Strains ,Neoplasm Proteins - Abstract
Mice lacking thrombopoietin (TPO), or its receptor c-Mpl, display defective megakaryocyte and platelet development and deficiencies in progenitor cells of multiple hematopoietic lineages. The contribution of alternative cytokines to thrombopoiesis in the absence of TPO signalling was examined in mpl-/- mice. Analysis of serum and organ-conditioned media showed no evidence of a compensatory overproduction of megakaryocytopoietic cytokines. However, consistent with a potential role in vivo, when injected into mpl-/- mice, interleukin-6 (IL-6) and leukemia inhibitory factor (LIF) retained the capacity to elevate megakaryocytes and their progenitors in hematopoietic tissues and increase circulating platelet numbers. However, double mutant mice bred to carry genetic defects both in c-Mpl and IL-3 or the alpha chain of the IL-3 receptor, displayed no greater deficiencies in megakaryocytes or platelets than mpl-deficient animals, suggesting absence of a physiologic role for IL-3 in the residual megakaryocytopoiesis and platelet production in these mice.
- Published
- 1998
39. Thrombopoietin in vitro and in vivo
- Author
-
W S, Alexander and C G, Begley
- Subjects
Blood Platelets ,Thrombopoietin ,Proto-Oncogene Proteins ,Stem Cells ,Humans ,Receptors, Cytokine ,Megakaryocytes ,Receptors, Thrombopoietin ,Recombinant Proteins ,Neoplasm Proteins ,Polyethylene Glycols ,Signal Transduction - Abstract
The characterization of the c-Mpl receptor resulted from studies on a murine retrovirus, and proved an important step in the identification of a key hemopoietic regulator. First proposed and named in 1958, the ultimate characterization of the long-awaited 'thrombopoietin' (TPO) came with the molecular cloning and characterization of the in vitro and in vivo properties of the c-Mpl ligand. Gene targeting experiments have demonstrated that the TPO/Mpl receptor signalling pathway is the principal physiological regulator of megakaryocytes and platelets. Analysis of signalling through c-Mpl has provided important insights into the function of this pathway, which, as with other members of the hemopoietin receptor family, involves activation of the JAK/STAT and Ras signalling cascades. Preclinical studies have documented a role for this molecule in overcoming thrombocytopenia following chemo/radiotherapy in several animal models. Clinical studies have demonstrated the safety and efficacy of Mpl ligand in elevating platelet counts. The identification of thrombopoietin has provided an important impetus in understanding megakaryocyte and platelet physiology, and provided a new therapeutic that will find application in a variety of clinical contexts.
- Published
- 1998
40. Oncostatin M induces the differentiation of breast cancer cells
- Author
-
A M, Douglas, S L, Grant, G A, Goss, D R, Clouston, R L, Sutherland, and C G, Begley
- Subjects
STAT3 Transcription Factor ,Cell Cycle ,Genes, myc ,Genes, fos ,Antineoplastic Agents ,Breast Neoplasms ,Cell Count ,Cell Differentiation ,Oncostatin M ,Growth Inhibitors ,DNA-Binding Proteins ,Gene Expression Regulation ,Cyclins ,Trans-Activators ,Tumor Cells, Cultured ,Humans ,Female ,Receptors, Growth Factor ,RNA, Messenger ,Growth Substances ,Peptides ,Cell Division ,Tumor Stem Cell Assay - Abstract
We have recently described the action of Oncostatin M (OSM) to inhibit the proliferation of breast cancer cells. In this study we examined the action of OSM on 2 breast cancer cell lines to further characterize the nature of OSM inhibition of cellular proliferation. Treatment with OSM for 6 days resulted in an approximately 2- to 5-fold decrease in cell number, which was independent of estrogen receptor status. Consistent with this, colony formation was reduced to approximately 50% when cells were exposed to OSM in primary agar cultures. Clonogenicity was further inhibited following 7 days treatment with OSM in monolayer cultures: the total number of clonogenic cells was suppressed approximately 10-fold. Analysis of cell cycle status in OSM-treated cells demonstrated a 40% reduction in the proportion of cells in S phase within 12 hr, with an increase in cells in G0/G1. After 6 days, there was a 10-fold reduction in the absolute number of cells in S phase in OSM-treated cultures. These changes were associated with striking changes in cellular morphology, including disruption of intercellular junctions and the production of lipid droplets. There was a 5-fold increase of c-fos and c-myc mRNA within 30 min of commencing treatment with OSM. In addition, in the ER positive cells there was a decrease in ER mRNA (evident within approximately 2 hr) and ER protein expression following treatment with OSM. Conversely, there was a 5-fold increase in epidermal growth factor receptor (EGFR) mRNA within 4 hr, and a 2.5-fold rise in mRNA for transforming growth factor alpha (TGF alpha). Thus, the inhibition of breast cancer cells by OSM was associated with decreased clonogenicity, a decrease in S phase cells and a variety of phenotypic changes, all consistent with the induction of differentiation.
- Published
- 1998
41. Factors involved in leukaemogenesis and haemopoiesis
- Author
-
A G, Elefanty, L, Robb, and C G, Begley
- Subjects
Gene Expression Regulation, Neoplastic ,Leukemia ,Animals ,Humans ,Hematopoiesis - Abstract
This review describes the chromosomal abnormalities in T-cell acute lymphoblastic leukaemia (ALL) which result in the over-expression of the gene SCL, which encodes a helix-loop-helix transcription factor. Also described are how gene targeting studies have revealed a key role for SCL in normal haemopoiesis. Next, the BCR-ABL fusion protein, seen in chronic myeloid leukaemia (CML) and in some patients with ALL, is discussed. Finally, the involvement of members of the core-binding factor (CBF) gene family in leukaemogenesis are described. Members of this gene family are involved in the generation of fusion proteins as a result of t(8;21) and inv(16), the most common translocations associated with acute myeloid leukaemia (AML). They provide a useful model of the way in which aberrant transcriptional function, brought about through genetic alterations, can modify haemopoietic development.
- Published
- 1998
42. Recombinant soluble interleukin-11 (IL-11) receptor alpha-chain can act as an IL-11 antagonist
- Author
-
D J, Curtis, D J, Hilton, B, Roberts, L, Murray, N, Nicola, and C G, Begley
- Subjects
Membrane Glycoproteins ,Molecular Sequence Data ,CHO Cells ,Receptors, Interleukin ,Interleukin-11 ,Recombinant Proteins ,Solubility ,Antigens, CD ,Cricetinae ,Cytokine Receptor gp130 ,Animals ,Receptors, Interleukin-11 ,Amino Acid Sequence ,Cell Division ,Signal Transduction - Abstract
We have expressed a soluble N-glycosylated form of the murine interleukin-11 (IL-11) receptor alpha-chain (sIL-11R) and examined signaling in cells expressing the gp130 molecule. In the presence of gp130 but not the transmembrane IL-11R, the sIL-11R mediated IL-11-dependent differentiation of M1 leukemic cells and proliferation in Ba/F3 cells. Early intracellular events stimulated by the sIL-11R including phosphorylation of gp130, STAT 3, and SHP-2 were similar to signaling through the transmembrane IL-11R. IL-11 bound to sIL-11R with low affinity (kd 10 to 50 nmol/L). Binding of sIL-11R to gp130 was IL-11 dependent with intermediate affinity (kd 1.5 to 3.0 nmol/L). However, the concentration of IL-11 required for signaling through the sIL-11R was 10- to 20-fold greater than that required for cells expressing the transmembrane IL-11R and gp130 in the absence of sIL-11R. Furthermore, the sIL-11R was capable of antagonizing the activity of IL-11 when tested on cells expressing the transmembrane IL-11R and gp130. We propose that the observed IL-11 antagonism by the sIL-11R may depend on limiting numbers of gp130 molecules on cells already expressing the transmembrane IL-11R.
- Published
- 1997
43. Expression of SCL is normal in transfusion-dependent Diamond-Blackfan anemia but other bHLH proteins are deficient
- Author
-
M Y, Zhang, G A, Clawson, N F, Olivieri, L L, Bell, C G, Begley, and B A, Miller
- Subjects
DNA-Binding Proteins ,Stem Cell Factor ,Erythrocytes ,Fanconi Anemia ,Gene Expression Regulation ,Proto-Oncogene Proteins ,Helix-Loop-Helix Motifs ,Basic Helix-Loop-Helix Transcription Factors ,Humans ,Blood Transfusion ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,Transcription Factors - Abstract
Basic helix-loop-helix proteins, which are tissue specific (SCL) or broadly expressed (E proteins), interact positively to regulate erythroid specific genes. Here, expression of SCL and two broadly expressed E proteins, E47 and HEB, was high early in erythroid differentiation and declined during maturation. Stimulation of erythroid progenitors/precursors with stem cell factor (SCF) enhanced SCL and E protein levels, one mechanism by which SCF may increase erythroid proliferation. Interactions between SCL and E proteins are competed by Id2, which binds and sequesters E proteins. Upregulation of Id2, demonstrated here late in erythroid differentiation, may downregulate genes involved in erythroid proliferation/differentiation. We examined expression of bHLH proteins in transfusion-dependent patients with Diamond-Blackfan anemia (DBA) to determine if these interactions are disrupted. In erythroblasts from patients, expression of SCL protein and mRNA was normal and SCL increased in response to SCF. However, E47 and HEB protein levels were significantly decreased. Id2 was strongly expressed in patients. Through reduction of SCL/E protein heterodimer formation, abnormal levels of bHLH transcription factors may affect expression of erythroid specific genes, such as beta globin. Stimulation of Diamond-Blackfan cells with SCF partially compensated for this defect, enhancing expression of E47, HEB, and SCL. SCF may function to increase SCL/E protein heterodimer formation, which may be one of the mechanisms through which SCF stimulates erythroid proliferation/differentiation in DBA.
- Published
- 1997
44. Hematopoietic-specific genes are not induced during in vitro differentiation of scl-null embryonic stem cells
- Author
-
A G, Elefanty, L, Robb, R, Birner, and C G, Begley
- Subjects
Helix-Loop-Helix Motifs ,Gene Expression ,Antigens, CD34 ,Cell Differentiation ,LIM Domain Proteins ,Hematopoietic Stem Cells ,Cell Line ,Hematopoiesis ,DNA-Binding Proteins ,GATA2 Transcription Factor ,Mice ,Proto-Oncogene Proteins ,Metalloproteins ,Basic Helix-Loop-Helix Transcription Factors ,Animals ,T-Cell Acute Lymphocytic Leukemia Protein 1 ,Adaptor Proteins, Signal Transducing ,Transcription Factors - Abstract
The helix-loop-helix transcription factor, scl, plays an essential role in hematopoietic development. Embryos in which the gene has been disrupted fail to develop yolk sac erythropoiesis, and scl-null embryonic stem cells do not contribute to hematopoiesis in chimeric mice. To analyze the molecular consequences of scl deficiency, we compared the gene expression profiles of control (wild-type and scl-heterozygous) and scl-null embryonic stem cells differentiated in vitro for up to 12 days. In control and scl-null embryoid bodies the temporal expression pattern of genes associated with the formation of ventral mesoderm, such as Brachyury, bone morphogenetic protein-4, and flk-1, was identical. Similarly, GATA-2, CD34, and c-kit, which are coexpressed in endothelial and hematopoietic lineages, were expressed normally in scl-null embryonic stem cell lines. However, hematopoietic-restricted genes, including the transcription factors GATA-1, EKLF, and PU.1 as well as globin genes and myeloperoxidase, were only expressed in wild-type and scl-heterozygous embryonic stem cells. Indirect immunofluorescence was used to confirm the observations that GATA-1 and globins were only present in control embryoid bodies but that CD34 was found on both control and scl-null embryoid bodies. These data extend the previous gene ablation studies and support a model whereby scl is absolutely required for commitment of a putative hemangioblast to the hematopoietic lineage but that it is dispensable for endothelial differentiation.
- Published
- 1997
45. Clinical studies with megakaryocyte growth and development factor (Mpl-ligand)
- Author
-
C G, Begley
- Subjects
Blood Platelets ,Thrombopoietin ,Stem Cells ,Cell Cycle ,Humans ,Cell Lineage ,Recombinant Proteins ,Randomized Controlled Trials as Topic - Abstract
The haemopoietic growth factor mpl-ligand (also known as thrombopoietin, and Megakaryocyte Growth and Development Factor [MGDF] is a recently cloned and characterized megakaryocyte-active factor. Administration of MGDF to humans was associated with a dose-related increase in the platelet count with maximum levels observed between days 12-18. Platelets had normal appearance and functioned normally in assays of platelet aggregation and ATP-release. There was no evidence of platelet activation as assessed by platelet surface markers. The earliest detectable effect of MGDF was an increase in early (reticulated) platelets by day 3-4. MGDF also hastened recovery from thrombocytopenia when given after myelosuppressive chemotherapy. MGDF caused mobilisation into the blood of progenitor cells of multiple haemopoietic lineages, and was synergistic with G-CSF in this action after chemotherapy. MGDF was well tolerated with no adverse effects directly attributable to its administration. Further clinical evaluation is on-going.
- Published
- 1997
46. The structural basis of the biological actions of the GM-CSF receptor
- Author
-
N A, Nicola, A, Smith, L, Robb, D, Metcalf, and C G, Begley
- Subjects
Cytoplasm ,Mice ,Structure-Activity Relationship ,Receptors, Granulocyte-Macrophage Colony-Stimulating Factor ,Animals ,Granulocyte-Macrophage Colony-Stimulating Factor ,Humans ,Interleukin-3 ,Dimerization ,Receptors, Interleukin-3 ,Signal Transduction - Abstract
The receptor for granulocyte/macrophage colony-stimulating factor (GM-CSF) consists of a ligand-specific low-affinity binding chain (GM-CSFR alpha) and a second chain that is required for high-affinity binding and signal transduction. This second chain is shared by the ligand-specific alpha-chains for the interleukin 3 (IL-3) and IL-5 receptors and is therefore called beta common (beta c). In mice but not humans the IL-3 receptor can also use a closely related but IL-3-specific beta-chain (beta IL-3). In order to define the contributions of each chain to receptor signalling we generated mice in which either beta c or beta IL-3 expression was deleted. beta IL-3 null mice were phenotypically normal but displayed a decreased responsiveness to IL-3 in vitro. beta c null mice, on the other hand, were unresponsive to GM-CSF or IL-5 but still responded to IL-3. These data demonstrated that GM-CSF and IL-5 receptors can use only one beta-chain for signalling (beta c) while IL-3 can effectively use either beta-chain. The hierarchical basis of receptor transmodulation was shown to result from this differential usage of beta-chains. To define the regions required for different types of cell signalling, we constructed human beta c mutants with successive cytoplasmic truncation. By the use of appropriate biological read-out systems we found that the cytoplasmic region of the receptor has a modular design with distinct domains required for cell proliferation, cell survival, differentiation and growth suppression. Appropriate targeting of these domains and the signalling pathways they initiate may provide highly specific cell therapies in the future.
- Published
- 1997
47. Retroviral transduction of human progenitor cells: use of granulocyte colony-stimulating factor plus stem cell factor to mobilize progenitor cells in vivo and stimulation by Flt3/Flk-2 ligand in vitro
- Author
-
N J, Elwood, H, Zogos, T, Willson, and C G, Begley
- Subjects
Stem Cell Factor ,Retroviridae ,fms-Like Tyrosine Kinase 3 ,Transduction, Genetic ,Proto-Oncogene Proteins ,Cell Cycle ,Granulocyte Colony-Stimulating Factor ,Humans ,Receptor Protein-Tyrosine Kinases ,Hematopoietic Stem Cells - Abstract
The clinical application of gene transfer is hindered by the availability of the multipotential stem cells and the difficulty in obtaining efficient retroviral transduction. To assess potential means by which gene transfer into human hemopoietic stem cells might be enhanced, the retroviral transduction efficiency of human bone marrow cells (BM) or peripheral blood progenitor cells (PBPC) was compared at multiple time points after in vivo administration of granulocyte colony-stimulating factor (G-CSF). This was further compared with the transduction efficiency of cells mobilized with G-CSF plus stem cell factor (SCF) in a cohort of patients randomized to receive either one or two growth factors and with normal BM function. Using the LNL6 retrovirus, retroviral transduction efficiencies of up to 19% were observed for both PBPC and BM (n = 26 patients). There was at least a 100-fold increase in PBPC with G-CSF alone and a further 30-fold increase in the total number of progenitor cells available for retroviral transduction using the combination of SCF plus G-CSF. However, pretreatment of patients with G-CSF with or without SCF did not enhance the retroviral infectability of growth factor-mobilized progenitor cells. The effect of the growth factor, Flk-2/Flt3 ligand (FL), was also examined with respect to retroviral transduction efficiency of human progenitor cells. FL plus IL-3 in vitro increased the retroviral transduction efficiency up to eightfold compared with results observed using other combinations of cytokines tested (P.001). These findings have clinical implications both for increasing the number of target cells for in vivo gene-marking/gene-therapy studies and improving the efficiency of gene transfer.
- Published
- 1996
48. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria
- Author
-
J F, McManus, C G, Begley, S, Sassa, and S, Ratnaike
- Subjects
Male ,Porphyria Cutanea Tarda ,Mutation ,Humans ,Uroporphyrinogen Decarboxylase ,Family ,Female ,Porphyria, Hepatoerythropoietic ,Sequence Analysis, DNA - Abstract
We describe five new mutations in the uroporphyrinogen decarboxylase (UROD) gene. All mutations were observed in conjunction with decreased erythrocyte UROD and clinical familial porphyria cutanea tarda (fPCT), (four families) or hepatoerythropoietic porphyria (HEP), (one family). The fPCT mutations included three point mutations that resulted in amino acid substitutions: a lysine to glutamine at amino acid position 253 (exon 7); a glycine to arginine at position 318 (exon 10); an isoleucine to threonine at position 334 (exon 10). The lysine to glutamine at amino acid position 253 was found in conjunction with a single C nucleotide deletion in exon 8 on the same allele of the UROD gene in the same family. This deletion resulted in a shift in the reading frame and the introduction of a premature stop codon 8 amino acids downstream. In the fourth family, a 31-bp deletion (nucleotides 828-858: exon 8) of the coding region, resulted in a frameshift and the introduction of a stop codon 19 amino acids downstream. A point mutation was observed in an individual diagnosed with HEP, resulting in an alanine to glycine change at amino acid position 80 and was present on both alleles. All mutations were confirmed in at least one other family member. The impact of these mutations on the function of the UROD protein was examined using in vitro protein expression and with activity assessed using pentacarboxylic acid porphyrinogen I as a substrate for UROD. Although three mutations reduced UROD activity to15% of normal, one resulted in a UROD protein with 50% functional activity and the other had near normal activity. These results indicate that many different genetic lesions of the UROD gene are associated with fPCT.
- Published
- 1996
49. Murine flt3 ligand protects M1 leukemic cells from LIF-induced differentiation and suppression of self-renewal
- Author
-
C G, Begley, J E, Rasko, D, Curtis, K, Takagi, D, Metcalf, D, Hilton, B, Roberts, N A, Nicola, and M T, Rossner
- Subjects
Molecular Sequence Data ,Transfection ,Leukemia Inhibitory Factor ,Polymerase Chain Reaction ,Cell Line ,Mice ,Fetus ,Chlorocebus aethiops ,Tumor Cells, Cultured ,Animals ,Humans ,RNA, Messenger ,DNA Primers ,Lymphokines ,Base Sequence ,Interleukin-6 ,Macrophage Colony-Stimulating Factor ,Membrane Proteins ,Cell Differentiation ,Templates, Genetic ,Blotting, Northern ,Hematopoietic Stem Cells ,Growth Inhibitors ,Recombinant Proteins ,Hematopoiesis ,Leukemia, Myeloid, Acute ,Liver - Abstract
Self-renewing cell divisions are an important characteristic exhibited by both normal hematopoietic stem cells and leukemic cell populations. We have examined the action of flt3/flk2 ligand (FL) on physiologic suppression of self-renewal during growth factor-induced differentiation of M1 leukemic cells. Unstimulated M1 cells expressed high levels of flt3 receptor mRNA and protein, with approximately 20,000 molecules present at the cell surface. Consistent with data obtained from normal macrophage populations, expression of both mRNA and protein for flt3 receptor was suppressed as cells were induced to differentiate into mature macrophages in response to leukemia inhibitory factor (LIF). Although FL alone had no detectable action on unstimulated M1 cells, an effect was revealed during LIF-induced differentiation. FL overcame LIF-induced suppression in clonal cultures of M1 cells, prevented morphologic changes associated with macrophage differentiation and interfered with the LIF-induced responsiveness of M1 cells to macrophage colony-stimulating factor (M-CSF). This action of FL was evident on both parental M1 cells and M1 cells whose differentiation program was perturbed by enforced expression of the transcription factor SCL. The action of FL was most striking in clone transfer experiments in which FL rescued M1 cells from LIF-induced suppression of self-renewal. The ability of FL to maintain self-renewal characteristics satisfies one of the criteria predicted for a stem-cell-active molecule and contrasts with the action of FL in stimulating proliferation and differentiation of normal hematopoietic cells.
- Published
- 1996
50. Functional inactivation in mice of the gene for the interleukin-3 (IL-3)-specific receptor beta-chain: implications for IL-3 function and the mechanism of receptor transmodulation in hematopoietic cells
- Author
-
N A, Nicola, L, Robb, D, Metcalf, D, Cary, C C, Drinkwater, and C G, Begley
- Subjects
Mice ,Base Sequence ,Bone Marrow ,Molecular Sequence Data ,Animals ,Hematopoietic Stem Cells ,Mice, Mutant Strains ,Receptors, Interleukin-3 ,Cell Line ,Signal Transduction - Abstract
The receptors for granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 and -5 (IL-3, IL-5) share a common signaling subunit (beta c). However, in the mouse, IL-3 can also use an alternative IL-3-specific receptor beta-chain (beta IL-3). To assess the relative contributions of beta c and beta IL-3 to IL-3 receptor formation and function, mice were generated in which the beta IL-3 gene was functionally inactivated by replacement of exons 9-13 with a neomycin resistance cassette. Bone marrow cells from these mice displayed a lower affinity IL-3 receptor than normal and were hyporesponsive to IL-3, but the mice displayed no obvious hematopoietic abnormalities. The data suggested that beta c and beta IL-3 are normally coexpressed on IL-3-responsive cells and have identical qualitative signaling capacities. Receptor transmodulation studies on bone marrow cells from wild-type, beta c -/-, and beta IL-3 -/- mice showed that the previously described hierarchical pattern of transmodulation was dependent on the relative numbers of both beta IL-3 and beta c receptor chains and also provided evidence for an unexpected interaction between beta c chains and G-CSF and M-CSF receptors.
- Published
- 1996
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.